Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis

Nicole Ngai Yung Tsang, Hau Chi So, Ka Yan Ng, Benjamin J Cowling, Gabriel M Leung, Dennis Kai Ming Ip

Summary

Background The comparative performance of different clinical sampling methods for diagnosis of SARS-CoV-2 infection by RT-PCR among populations with suspected infection remains unclear. This meta-analysis aims to systematically compare the diagnostic performance of different clinical specimen collection methods.

Methods In this systematic review and meta-analysis, we systematically searched PubMed, Embase, MEDLINE, Web of Science, medRxiv, bioRxiv, SSRN, and Research Square from Jan 1, 2000, to Nov 16, 2020. We included original clinical studies that examined the performance of nasopharyngeal swabs and any additional respiratory specimens for the diagnosis of SARS-CoV-2 infection among individuals presenting in ambulatory care. Studies without data on paired samples, or those that only examined different samples from confirmed SARS-CoV-2 cases were not useful for examining diagnostic performance of a test and were excluded. Diagnostic performance, including sensitivity, specificity, positive predictive value, and negative predictive value, was examined using random effects models and double arcsine transformation.

Findings Of the 5577 studies identified in our search, 23 studies including 7973 participants with 16/762 respiratory samples were included. Respiratory specimens examined in these studies included 7973 nasopharyngeal swabs, 1622 nasal swabs, 6110 saliva samples, 338 throat swabs, and 719 pooled nasal and throat swabs. Using nasopharyngeal swabs as the gold standard, pooled nasal and throat swabs gave the highest sensitivity of 97% (95% CI 93–100), whereas lower sensitivities were achieved by saliva (85%, 75–93) and nasal swabs (86%, 77–93) and a much lower sensitivity by throat swabs (68%, 35–94). A comparably high positive predictive value was obtained by pooled nasal and throat (97%, 90–100) and nasal swabs (96%, 87–100) and a slightly lower positive predictive value by saliva (93%, 88–97). Throat swabs have the lowest positive predictive value of 75% (95% CI 45–96). Comparably high specificities (range 97–99%) and negative predictive value (range 95–99%) were observed among different clinical specimens. Comparison between health-care-worker collection and self-collection for pooled nasal and throat swabs and nasal swabs showed comparable diagnostic performance. No significant heterogeneity was observed in the analysis of pooled nasal and throat swabs and throat swabs, whereas moderate to substantial heterogeneity (I² ≥ 30%) was observed in studies on saliva and nasal swabs.

Interpretation Our review suggests that, compared with the gold standard of nasopharyngeal swabs, pooled nasal and throat swabs offered the best diagnostic performance of the alternative sampling approaches for diagnosis of SARS-CoV-2 infection in ambulatory care. Saliva and nasal swabs gave comparable and very good diagnostic performance and are clinically acceptable alternative specimen collection methods. Throat swabs gave a much lower sensitivity and positive predictive value and should not be recommended. Self-collection for pooled nasal and throat swabs and nasal swabs was not associated with any significant impairment of diagnostic accuracy. Our results also provide a useful reference framework for the proper interpretation of SARS-CoV-2 testing results using different clinical specimens.

Funding Hong Kong Research Grants Council.

Copyright © 2021 Elsevier Ltd. All rights reserved.
RT-PCR is regarded as the gold-standard laboratory technique for the identification of SARS-CoV-2 in a clinical setting. In people with confirmed SARS-CoV-2 infection, lower respiratory tract specimens were generally reported to have higher positivity rates than other biosamples, a finding consistent with the current understanding of the pathogenetic mechanism of SARS-CoV-2 infection over the disease course. For clinical diagnosis of the infection, a variety of respiratory specimens are used for laboratory testing, with nasopharyngeal swabs so far regarded as the gold-standard sampling method for the diagnosis of SARS-CoV-2 infection. However, several drawbacks have hindered the widespread use of nasopharyngeal swabs in ambulatory care settings, including the technical difficulty of specimen collection, discomfort associated with the procedure, manpower implications, and the requirement for trained and technically experienced health-care workers, high-level personal protective equipment, and standardised negative-pressure settings, which are often not readily available, resulting in increased occupational risk exposure to health-care workers.

With the aim of improving the scalability of SARS-CoV-2 testing in ambulatory care settings under heightened demand, several alternative sampling approaches have been explored, including pooled nasal and throat swabs, saliva, nasal swabs, and oropharyngeal swabs (throat swabs). These alternative approaches to SARS-CoV-2 testing have the theoretical advantages of reduced invasiveness and simpler procedures than nasopharyngeal swabs, potentially making testing more acceptable and accessible. The less stringent manpower and expertise requirement also allows for self-collection to be explored, which might also help to reduce the risk to health-care workers. However, a comprehensive understanding of the comparative diagnostic performance of these alternative sampling approaches is needed.

To fill this research gap, we did a systematic review and meta-analysis examining the comparative performance of different clinical sampling methods for SARS-CoV-2 testing in ambulatory care settings and assessing sensitivity, specificity, positive predictive value, and negative predictive value. Our review suggested that compared with the gold standard of nasopharyngeal swabs, pooled nasal and throat swabs offer the best diagnostic performance and represent the optimal alternative sampling approach. Saliva and nasal swabs also gave very good and comparable performance and are clinically acceptable alternative specimen collection methods for the accurate diagnosis of SARS-CoV-2 infection. For all the three methods, self-collection of these clinical specimens did not associate with any significant impairment of diagnostic accuracy.

### Research in context

#### Evidence before this study

Accurate and efficient diagnosis of SARS-CoV-2 infection is required for downstream clinical and public health procedures. Although several studies have examined the use of different respiratory specimens for detection of SARS-CoV-2 RNA by RT-PCR, the comparative performance of different clinical sampling methods among population with suspected infection remains unclear. A search of PubMed on Feb 20, 2021, using search terms describing SARS-CoV-2 infection and different respiratory specimens and with no language restrictions identified ten reviews on the issue. Five of these reviews exclusively included studies of patients with confirmed COVID-19 and only reported the agreement of positivity rate of different respiratory specimens in infected people. Because of the absence of non-infected participants in these studies, they are not useful in assessing diagnostic performance in identifying or excluding the disease among individuals with suspected infection in terms of false positivity or negative predictive value. The other five reviews only examined the performance of saliva in comparison with nasopharyngeal swabs, rather than giving a comprehensive comparison of all commonly used sampling methods. No review has examined the performance of pooled nasal and throat swabs, nasal swabs, or throat swabs or reported positive and negative predictive values of different sampling approaches, two indicators necessary for understanding the implication of testing results from the perspective of both patients and health-care workers. Additionally, none of the reviews examined the comparative performance of samples collected by health-care workers or by self-collection.

#### Added value of this study

To fill this research gap, we did a systematic review and meta-analysis of studies comparing different clinical sampling methods of respiratory specimens for the detection of SARS-CoV-2 RNA. We systematically searched PubMed, Embase, MEDLINE, Web of Science, medRxiv, bioRxiv, SSRN, and Research Square from Jan 1, 2000, to Nov 16, 2020. We included original clinical studies that examined the performance of nasopharyngeal swabs and any additional respiratory specimens for the diagnosis of SARS-CoV-2 infection among individuals presenting in ambulatory care. We examined diagnostic performance, including sensitivity, specificity, positive predictive value, and negative predictive value using random effects models and double arcsine transformation.

To our knowledge, this is the first systematic review and meta-analysis examining the comparative diagnostic performance of different clinical sampling methods for SARS-CoV-2 testing in an ambulatory care setting and assessing sensitivity, specificity, positive predictive value, and negative predictive value. Our review suggested that compared with the gold standard of nasopharyngeal swabs, pooled nasal and throat swabs offer the best diagnostic performance and represent the optimal alternative sampling approach. Saliva and nasal swabs also gave very good and comparable performance and are clinically acceptable alternative specimen collection methods for the accurate diagnosis of SARS-CoV-2 infection. For all the three methods, self-collection of these clinical specimens did not associate with any significant impairment of diagnostic accuracy.

#### Implications of all the available evidence

Our results provide a useful reference framework for the proper interpretation of SARS-CoV-2 testing results using different clinical specimens. They also support the use of pooled nasal and throat swabs, saliva, and nasal swabs as alternative sampling methods for SARS-CoV-2 RNA detection and the use of self-collection to facilitate efficient scaling up of testing in appropriate community settings.
Although several published studies have investigated the performance of various alternative sampling approaches for SARS-CoV-2 testing, they generally had methodological limitations, including the inclusion of only confirmed positive cases,\textsuperscript{23–25} inadequate sample size,\textsuperscript{26} absence of differentiation between populations with suspected and confirmed infection,\textsuperscript{27–28} absence of comparison with a suitable gold standard,\textsuperscript{27} reporting of viral loads alone,\textsuperscript{29} or comparison of aggregated result rather than use of a head-to-head comparison.\textsuperscript{29} Ten reviews have tried to summarise existing evidence, but similarly all had multiple design limitations, and neither addressed clinically important measures such as positive or negative predictive values nor compared samples collected by health-care workers or by self-collection.\textsuperscript{12,13,27–35}

A systematic review of the diagnostic accuracy of different sampling approaches for SARS-CoV-2 testing in individuals with suspected infection is therefore needed to properly evaluate their diagnostic performance. We aimed to systematically examine the comparative diagnostic performance of different clinical specimen collection methods for SARS-CoV-2 in populations with suspected infection presenting to ambulatory care settings, with a view to informing clinical and public health workers on the best tool for the diagnosis of SARS-CoV-2 infection in an evidence-based manner.

Methods

Search strategy and selection criteria

For this systematic review and meta-analysis, a standardised search was done in PubMed, OVID MEDLINE, Embase, and Web of Science, using the search term “(((novel coronavirus) OR (ncov)) OR (SARS CoV 2)) OR (COVID19)) OR (covid)) AND (((saliva) OR (nasopharyngeal swab)) OR (nasal swab)) OR (throat swab)) OR (naso/oropharyngeal aspirate))”. Given the role of preprints in timely dissemination of research studies during the COVID-19 pandemic, a search of the medRxiv and bioRxiv servers was also done using the search term “((SARS CoV 2) OR COVID19 OR covid) AND (saliva OR nasopharyngeal OR nasal OR throat OR oropharyngeal OR swab)”. We also searched SSRN and Research Square for preprint literature containing the word “nasopharyngeal” in title, abstract, and keywords. The search on preprint servers was simplified because of their reduced search functionality. The search was done on Nov 16, 2020, with no language restrictions. Additional relevant articles from the reference sections were also reviewed.

Original clinical studies comparing the performance of nasopharyngeal swabs and any additional respiratory specimens for the diagnosis of suspected SARS-CoV-2 infection in individuals presenting in ambulatory care settings were included. Studies without data on paired samples or those that only examined different types of sample from confirmed SARS-CoV-2 cases were excluded. Studies examining samples from confirmed cases can only report the positivity rate, result concordance, and viral load of different samples, which are not useful for examining the diagnostic performance of a test as a public health tool. Because clinical diagnosis involves the correct identification of individuals with infection from individuals with suspected clinical features or exposure history, only studies involving populations with suspected infection, including both positive and negative cases, allow the examination of diagnostic performance, through the calculation of sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV; appendix p 1). Studies testing only one part of a collection of specimens were excluded from this review to avoid potential bias due to selective testing.

Two authors (NNYT and HCS) screened articles, with disagreement resolved by consensus together with a third author (DKMI). Studies identified from different databases were de-duplicated after screening. Three authors (NNYT, HCS, and KYN) independently extracted data from the included studies, with disagreement resolved by consensus with a fourth author (DKMI). Two authors (NNYT and DKMI) assessed studies for methodological quality, including risk of bias and applicability, by use of the Scottish Intercollegiate Guidelines Network methodology checklist, adapted from Quality Assessment of Diagnostic Accuracy Studies tool for diagnostic studies.\textsuperscript{37,38}

Data analysis

For included studies, either individual data or summary estimates of sample size, number of true positive, true negative, false positive, and false negative results in each study were extracted. By use of a standardised data extraction chart, we also retrieved information on study period, country, setting, disease prevalence, symptomatic status of population, sampling approaches, peer-reviewed status, and target genes assessed. These findings were checked for agreement.

The sensitivity, specificity, PPV, and NPV of RT-PCR tests and the 95% CIs were calculated and compared for different sampling methods, including pooled nasal and throat swabs, saliva, nasal swabs, throat swabs, with random effects meta-analyses using the inverse variance method\textsuperscript{26} and restricted maximum likelihood estimator for heterogeneity,\textsuperscript{40,41} with nasopharyngeal swabs as the reference because they are preferred by established guidelines. Freeman-Tukey double arcsine transformation was incorporated for normalising and stabilising the variance of sampling distribution of proportions, and pooled estimates were back-transformed using harmonic mean.\textsuperscript{64} Sensitivity, specificity, PPV, and NPV of alternative clinical specimens were compared by constructing a fixed-effect model using the standard errors obtained from the random effects meta-analysis. Q statistic and its p value were calculated to test whether effect sizes depart
from homogeneity, and $I^2$ statistic and its 95% CI were calculated to examine the proportion of dispersion due to heterogeneity.43,44 To assess possible factors contributing to heterogeneity, subgroup analyses were done for saliva, nasal swabs, and pooled nasal and throat swabs. Subgroup analysis for throat swab was precluded by the availability of only two studies. Study-level characteristics stratified included disease prevalence (<10% or ≥10%), geographical regions (USA or non-USA), symptomatic status of population (symptomatic only or symptomatic and asymptomatic), peer-reviewed status (yes or no), and number of target genes assessed in RT-PCR (one gene or two or more genes). For nasal swabs and pooled nasal and throat swabs, additional factors stratified included collection personnel (by health-care worker or self-collected by patient), swab materials (flocked or unflocked), and number of nostrils sampled (one or both). Comparison between samples collected by health-care workers and self-collection was presented using forest plots for pooled nasal and throat swabs and nasal swabs, as allowable by the availability of studies examined the two different approaches. Scatterplots were used to present associations between the disease prevalence and the four performance indicators in included studies. Data were analysed with the metafor (version 2.4.0) and robvis (version 0.3.0) packages in R (version 3.6.0).

Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results
From the 5577 studies identified in our search, 2498 duplicates were excluded. After screening the titles and abstracts of the remaining articles, 150 full texts were screened (figure 1). On the basis of our selection criteria, 127 of those studies were excluded and 23 studies21,47–69 met our inclusion criteria (table). Of these, 14 studies were from the USA,21,47–59 four were from European countries,60–63 two were from Eastern Mediterranean countries,64,65 and the rest were from Canada,66 India,67 and China.14 7973 individuals with suspected SARS-CoV-2 infection, who were mostly symptomatic outpatients presenting to dedicated testing sites or emergency departments, were included from the 23 eligible studies. All studies used nasopharyngeal swabs collected by health-care workers as the reference gold standard, three studies examined pooled nasal and throat swabs (two on samples collected by health-care workers and one on self-collected samples), 13 examined self-collected saliva, seven examined nasal swabs (two on samples collected by health-care workers and five on self-collected samples), and two examined throat swabs collected by health-care workers. 16762 respiratory samples were included in our analysis, including 7973 nasopharyngeal swabs from each of the participants in the 23 studies and 1622 nasal swabs from seven studies, 6110 saliva samples from 13 studies, 338 throat swabs from two studies, and 719 pooled nasal and throat swabs from three studies. Among the 7973 individuals with suspected SARS-CoV-2 infection included in these studies, 1353 patients tested positive by nasopharyngeal swabs, giving an overall prevalence of 17·0% (95% CI 16·2–17·8). For individual studies, the prevalence of SARS-CoV-2 infection ranged from 4·3% to 84·1% (table).

Sensitivity measures the ability of a diagnostic test to correctly identify patients who have the disease with a positive test result. Using nasopharyngeal swabs as the reference, pooled nasal and throat swabs gave a sensitivity of 97% (95% CI 93–100), whereas saliva achieved a sensitivity of 85% (75–93), nasal swabs 86% (77–93), and throat swabs 68% (35–94; figure 2). The sensitivity of SARS-CoV-2 testing by pooled nasal and throat swabs was significantly higher than that of throat swabs ($p=0.017$). Specificity measures the ability of a test to

---

**Figure 1: Study profile**

5568 records identified through database searching
1379 through PubMed
1491 through Embase
602 through MEDLINE
1084 through Web of Science
508 through medRxiv
114 through bioRxiv
107 through SSRN
283 through Research Square

9 records identified through other sources

3079 records after duplicates removed

3079 records screened

2929 records excluded after review of abstract and title

150 full-text articles assessed for eligibility

127 full-text articles excluded

17 had no original data

26 had insufficient data

68 included an ineligible population

16 did not include comparisons with nasopharyngeal swabs

23 studies included in qualitative synthesis

23 studies included in quantitative synthesis (meta-analysis)
| Author (year) | Study period | Location | Setting | Prevalence of SARS-CoV-2 (95% CI) | Patient characteristics | Sampling approaches | Target gene | Peer review | Evidence rating |
|--------------|--------------|----------|---------|---------------------------------|-------------------------|---------------------|-------------|-------------|----------------|
| Kojima et al (2020) | Not reported | USA | Dedicated COVID-19 drive-through testing sites or specimen collection through home visit | 48.8% (33.3–64.5) | Symptomatic and asymptomatic outpatients | Nasopharyngeal swab, self-collected nasal swab | N | Yes | High |
| Landry et al (2020) | April 16, 2020–April 28, 2020 | USA | Dedicated COVID-19 drive-through testing sites | 26.6% (19.1–35.3) | Symptomatic outpatients | Nasopharyngeal swab, saliva | N | Yes | High |
| McCormick-Baw et al (2020) | Not reported | USA | Accident and emergency department | 31.6% (24.4–39.6) | Symptomatic outpatients | Nasopharyngeal swab, saliva | N | Yes | High |
| Migueres et al (2020) | Not reported | France | Hospital | 33.3% (25.1–42.4) | Symptomatic and asymptomatic outpatients | Nasopharyngeal swab, saliva | RdRp | Yes | High |
| Miller et al (2020) | Not reported | USA | Two primary care medicine facilities | 37.4% (27.4–48.1) | Symptomatic and asymptomatic outpatients | Nasopharyngeal swab, saliva | N | No | High |
| Callahan et al (2020) | Not reported | USA | Dedicated COVID-19 drive-through or walk-up testing sites | 23.3% (13.4–36.0) | Symptomatic and asymptomatic outpatients | Nasopharyngeal swab, self-collected nasal swab | N | No | High |
| Pérez et al (2020) | March, 2020 | France | Hospital | 84.1% (69.9–93.4) | Symptomatic outpatients | Nasopharyngeal swab, nasal swab | N, S | Yes | High |
| Tu et al (2020) | March 16, 2020–March 31, 2020 | USA | Ambulatory clinics | 10.3% (7.8–13.3) | Symptomatic outpatients | Nasopharyngeal swab, self-collected nasal and mid-turbinate swabs | N | Yes | High |
| Patel et al (2020) | Jan 27, 2020–Feb 29, 2020 | USA | Sample submitted through Centers for Disease Control and Prevention | 15.1% (9.7–21.9) | Symptomatic outpatients ≤7 days since illness onset | Nasopharyngeal swab, oropharyngeal swab | N | Yes | High |
| Wang et al (2020) | Feb 16, 2020–March 2, 2020 | China | Hospital | 7.3% (4.6–11.9) | Outpatients with fever and x-ray abnormality | Nasopharyngeal swab, oropharyngeal swab | N, ORF | Yes | High |
| Lelliclanc et al (2020) | Not reported | Canada | Dedicated COVID-19 testing sites | 17.9% (12.7–24.1) | Symptomatic and asymptomatic outpatients | Nasopharyngeal swab, pooled nasal and throat swab | E, ORF | Yes | High |
| Vlek et al (2020) | April 21, 2020–April 29, 2020 | Netherlands | Hospital | 23.4% (15.7–32.5) | Symptomatic health-care workers | Nasopharyngeal swab, pooled nasal and throat swab | E | Yes | High |
| Griesemer et al (2020) | March 20, 2020–March 26, 2020 | USA | Two dedicated COVID-19 drive-through testing sites | 22.2% (18.5–26.3) | Symptomatic and asymptomatic outpatients | Nasopharyngeal swab, nasal swab, saliva | N | No | High |
| Hanson et al (2020) | May 29, 2020–June 25, 2020 | USA | Dedicated COVID-19 drive-through testing sites | 22.6% (18.3–27.3) | Symptomatic outpatients | Nasopharyngeal swab, saliva, self-collected nasal swab | ORF | Yes | High |
| Altawalah et al (2020) | July 19, 2020–July 21, 2020 | Kuwait | Hospital | 38.6% (35.4–41.9) | Suspected COVID-19 admitted case | Nasopharyngeal swab, saliva | N, S, ORF | Yes | High |
| Barat et al (2020) | July 13, 2020–Sept 18, 2020 | USA | Drive-through testing sites and emergency department | 6.4% (4.3–9.1) | Symptomatic outpatients | Nasopharyngeal swab, saliva | N | Yes | High |
| Procop et al (2020) | Not reported | USA | Outpatient testing centre (ie, drive-through) | 17.6% (12.8–23.3) | Symptomatic outpatients | Nasopharyngeal swab, saliva | N | Yes | High |
| Senok et al (2020) | June 29, 2020–July 14, 2020 | United Arab Emirates | Community-based COVID-19 screening facility | 6.5% (4.3–9.4) | Symptomatic and asymptomatic outpatients | Nasopharyngeal swab, saliva | N | Yes | High |
| McCulloch et al (2020) | March 31, 2020–April 13, 2020 | USA | Drive-through testing clinics | 7.1% (3.6–12.4) | Symptomatic outpatients and health-care workers | Nasopharyngeal swab, self-collected nasal swab | N | Yes | High |
| Shaki et al (2020) | Not reported | USA | Dedicated COVID-19 drive-through testing sites | 27.7% (23.5–32.3) | Symptomatic outpatients | Nasopharyngeal swab, self-collected pooled nasal and throat swab | E, ORF | Yes | High |
| Bhattacharya et al (2020) | Not reported | India | Hospital | 78.4% (67.3–87.1) | Symptomatic suspected patients | Nasopharyngeal swab, saliva | E, ORF | No | Acceptable |
| Yee et al (2020) | June 8, 2020–Aug 28, 2020 | USA | Hospital | 22.7% (17.9–28.1) | Symptomatic and asymptomatic suspected patients | Nasopharyngeal swab, saliva | N, S, ORF | No | Acceptable |
| Mestdaghi et al (2020) | June, 2020–July, 2020 | Belgium | Triage centres | 4.3% (3.5–5.2) | Symptomatic and asymptomatic outpatients | Nasopharyngeal swab, saliva | E | No | Acceptable |

E=envelope protein. N=nucleocapsid protein. ORF=open reading frame. RdRp=RNA-dependent RNA-polymerase. S=spike protein.
correctly identify people who do not have the disease with a negative test result. Comparably high specificities, ranging from 97% to 99%, were observed among all four clinical specimen collection methods (figure 2).

PPV represents the probability that a patient truly has the disease after having a positive test result. The highest PPV was given by pooled nasal and throat (97%, 95% CI 90–100) and nasal swabs (96%, 87–100), followed by saliva (93%, 88–97) and throat swabs (75%, 45–96; figure 3). NPV represents the probability that a patient truly does not have the disease after a negative test result. NPVs were generally comparable among different
A Nasopharyngeal swab and pooled nasal and throat swab

| Study                  | True positive | False positive | False negative | True negative | Total |
|------------------------|---------------|----------------|----------------|---------------|-------|
| LeBlanc et al          | 31            | 2              | 3              | 354           | 190   |
| Vlek et al             | 25            | 2              | 0              | 80            | 107   |
| Shahri et al           | 113           | 1              | 4              | 304           | 422   |
| Random effects model   |               |                |                |               |       |

Weight (%) PPV Weight (%) NPV
4.31 0.94 (0.83–1.00) 11.82 0.98 (0.95–1.00)
2.95 0.93 (0.79–1.00) 5.56 1.00 (0.98–1.00)
9.74 0.99 (0.96–1.00) 3.62 0.99 (0.97–1.00)

(Q=4.84, p=0.089, I²=57.4%) (Q=1.86, p=0.39, I²=0.0%)

B Nasopharyngeal swab and saliva

| Study                  | True positive | False positive | False negative | True negative | Total |
|------------------------|---------------|----------------|----------------|---------------|-------|
| Landry et al           | 28            | 2              | 5              | 89            | 124   |
| McCormick-Frune et al  | 47            | 1              | 2              | 105           | 155   |
| Migayres et al         | 34            | 3              | 7              | 79            | 123   |
| Miller et al           | 33            | 2              | 1              | 55            | 91    |
| Griesemer et al        | 85            | 2              | 18             | 358           | 463   |
| Hanson et al           | 75            | 6              | 5              | 268           | 354   |
| Altawalah et al        | 287           | 18             | 57             | 529           | 891   |
| Barat et al            | 25            | 1              | 4              | 421           | 451   |
| Procop et al           | 38            | 1              | 0              | 177           | 216   |
| Senok et al            | 19            | 9              | 7              | 366           | 401   |
| Bhattacharya et al     | 53            | 0              | 5              | 16            | 74    |
| Yee et al              | 49            | 8              | 13             | 203           | 273   |
| Mestdagh et al         | 33            | 12             | 74             | 2375          | 2494  |
| Random effects model   |               |                |                |               |       |

Weight (%) PPV Weight (%) NPV
1.39 0.93 (0.81–1.00) 0.50 0.95 (0.89–0.98)
6.53 0.98 (0.91–1.00) 1.44 0.98 (0.94–1.00)
1.46 0.92 (0.86–0.99) 0.31 0.92 (0.85–0.97)
1.86 0.94 (0.84–1.00) 0.78 0.98 (0.92–1.00)
10.86 0.98 (0.93–1.00) 2.30 0.95 (0.93–0.97)
3.60 0.91 (0.86–0.97) 3.99 0.98 (0.96–0.99)
17.37 0.94 (0.91–0.96) 1.89 0.90 (0.88–0.93)
2.00 0.96 (0.84–1.00) 16.76 0.99 (0.98–1.00)
3.43 0.97 (0.89–1.00) 146.76 1.00 (0.99–1.00)
0.41 0.68 (0.49–0.84) 5.44 0.98 (0.96–0.99)
47.98 1.00 (0.97–1.00) 0.03 0.76 (0.75–0.92)
1.47 0.86 (0.76–0.94) 1.06 0.94 (0.90–0.97)
0.73 0.73 (0.59–0.85) 23.71 0.97 (0.96–0.98)
0.93 0.88 (0.97) 0.97 0.94 (0.97–0.98)

(Q=46.76, p=0.0001, I²=79.3%) (Q=96.46, p=0.0001, I²=90.6%)

C Nasopharyngeal swab and nasal swab

| Study                  | True positive | False positive | False negative | True negative | Total |
|------------------------|---------------|----------------|----------------|---------------|-------|
| Caffah et al           | 7             | 2              | 7              | 44            | 60    |
| Kojima et al           | 19            | 4              | 2              | 18            | 43    |
| Per et al              | 33            | 0              | 4              | 7             | 44    |
| Te et al               | 50            | 0              | 2              | 452           | 504   |
| Griesemer et al        | 86            | 0              | 17             | 350           | 463   |
| Hanson et al           | 69            | 1              | 11             | 273           | 354   |
| McCulloch et al        | 9             | 3              | 2              | 140           | 154   |
| Random effects model   |               |                |                |               |       |

Weight (%) PPV Weight (%) NPV
0.08 0.78 (0.44–0.99) 0.36 0.86 (0.75–0.95)
0.24 0.83 (0.64–0.96) 0.18 0.90 (0.72–1.00)
9.31 1.00 (0.95–1.00) 0.04 0.64 (0.33–0.90)
21.20 1.00 (0.97–1.00) 0.77 0.76 (0.99–1.00)
62.30 1.00 (0.98–1.00) 7.49 0.95 (0.93–0.97)
6.78 0.99 (0.94–1.00) 6.44 0.96 (0.94–0.98)
0.10 0.75 (0.46–0.96) 7.73 0.99 (0.96–1.00)
0.96 0.87 (1.00) 0.95 0.88 (0.99)

(Q=26.38, p=0.0002, I²=84.0%) (Q=45.70, p=0.0001, I²=93.3%)

D Nasopharyngeal swab and throat swab

| Study                  | True positive | False positive | False negative | True negative | Total |
|------------------------|---------------|----------------|----------------|---------------|-------|
| Patel et al            | 18            | 3              | 4              | 121           | 146   |
| Wang et al             | 7             | 5              | 7              | 123           | 192   |
| Random effects model   |               |                |                |               |       |

Weight (%) PPV Weight (%) NPV
7.52 0.86 (0.67–0.98) 44.68 0.97 (0.93–0.99)
3.48 0.58 (0.29–0.85) 55.32 0.96 (0.93–0.99)
1.75 0.45 (0.32–0.76) 1.96 0.94 (0.93–0.98)

(Q=2.81, p=0.093, I²=64.5%) (Q=0.07, p=0.80, I²=0.0%)

Figure 3: Meta-analysis of PPV and NPV, using nasopharyngeal swab as reference standard
Forest plots of PPV and NPV. Squares (proportional to the sample size, disease prevalence, and heterogeneity) represent point estimates. NPV=negative predictive value. PPV=positive predictive value.

clinical specimens, with highest value of 99% (95% CI 98–100) given by pooled nasal and throat swabs, followed by saliva (97%, 95% CI 94–98), throat swabs (96%, 94–98), and nasal swabs (95%, 88–99; figure 3).

No significant heterogeneity was observed in the analysis of pooled nasal and throat swab (I² of different diagnostic estimates ranged between 0% and 57%) and throat swabs (I² of different diagnostic estimates ranged between 0% and 74%; appendix pp 7–10). Sensitivity, specificity, NPV, and PPV from studies on saliva and nasal swabs were more heterogeneous (I² ranged between 69% and 93%; appendix pp 7–10), with some particularly low
values from studies with a smaller inverse-variance weighting. Generally no significant differences of the diagnostic performance indicators was found on stratified analyses for pooled nasal and throat swab. For saliva, a lower sensitivity was observed for studies with disease prevalence of less than 10% (64% vs 90%), studies done outside the USA (74% vs 91%), studies involving asymptomatic individuals in the samples (76% vs 94%),
preprints (79% vs 89%), or studies that tested for one target gene in the PCR assay (75% vs 90%; appendix pp 7–10). A lower PPV in saliva was found for studies with a disease prevalence of less than 10% (81% vs 95%; appendix pp 7–10). For nasal swabs, a lower sensitivity was observed for studies that included samples from asymptomatic individuals (78% vs 90%) and in preprints (70% vs 91%; appendix pp 7–10). A lower PPV in nasal swabs was found for studies with a disease prevalence of less than 10% (75% vs 98%) and a lower NPV for studies done outside the USA (64% vs 96%; appendix pp 7–10). Heterogeneity generally remained moderate to substantial (I²=30%) in most stratified analyses, as defined according to the Cochrane Handbook for Systematic Reviews of Interventions.

For pooled nasal and throat swabs, stratified comparison of samples collected by health-care workers (two studies) and self-collected samples (one study) showed no statistical difference in sensitivity, specificity, and NPV between the two approaches, and a slightly higher PPV for self-collected swabs (93% vs 99%; figure 4). For nasal swabs, all four indicators were similar between samples collected by health-care workers from two studies and self-collected samples from five studies (figure 4). Stratified comparison of collection personnel was not done for saliva and throat swabs, because all 13 studies on saliva were self-collected and both studies on throat swabs were by collection by health-care workers. Scatterplots of the performance indicators against the range of disease prevalence of individual studies (from 4.3% to 84.1%) indicated that sensitivities and specificities were relatively stable across different disease prevalences (appendix p 2). However, PPVs showed an increasing trend for higher prevalence and a decreasing trend for lower prevalence (appendix p 2), whereas NPVs showed a decreasing trend for higher prevalence and an increasing trend for lower prevalence (appendix p 2).

Quality assessment showed that all included studies were of good or acceptable quality and low risk of bias (appendix p 3). Because six of the 23 studies were published on platforms without a formal peer-review process, a sensitivity analysis excluding these six articles was done. This analysis gave a similar result to the full analysis, with pooled nasal and throat swabs giving the highest sensitivity and PPV and a generally high specificity and NPV for all sample types (appendix pp 4–6).

**Discussion**

To our knowledge, this is the first systematic review and meta-analysis examining alternative specimen collection methods for SARS-CoV-2 RT-PCR testing, and reports the pooled analysis of sensitivity, specificity, PPV, and NPV to inform a comprehensive evaluation of the relative diagnostic performance of different sampling approaches for the diagnosis of SARS-CoV-2 infection among suspected cases. By comparing all the performance indicators of alternative specimen collection methods to the same reference gold standard (ie, nasopharyngeal swabs) and including only studies with standardised RT-PCR testing procedures, our review minimised potential bias from variation of testing techniques and allowed for a scientifically valid assessment of different sampling approaches.

Our findings showed that pooled nasal and throat swabs offered the best diagnostic performance, with high sensitivity (97%), specificity (99%), PPV (97%), and NPV (99%), making it the best alternative option for accurate laboratory testing. This result is compatible with that found by Lee and colleagues, who also report a high percentage positive of combined oropharyngeal and nasal swabs, comparable to that of nasopharyngeal swabs. We also found that saliva and nasal swabs gave similar and very good diagnostic performance, with moderate sensitivities and high specificities, PPVs, and NPVs. This result is compatible with the moderate sensitivity observed in two previous reviews, but contrasts with the lower percentage positive of saliva and nasal swabs in Lee et al. These three alternative specimens should represent clinically acceptable alternatives to nasopharyngeal swabs for diagnosis of SARS-CoV-2 infection in the ambulatory care setting. Throat swabs gave a much lower sensitivity and PPV than nasopharyngeal swabs, a finding similar to that of Mohammadi and colleagues, indicating that it is a worse specimen collection method and should not be recommended for the diagnosis of SARS-CoV-2 infection.

In a traditional screening setting, false positive results are associated with the concern of unnecessary invasive confirmatory tests and its associated risk and stress. In the context of the COVID-19 epidemic, cases labelled as positive might be relabelled as non-cases after they are followed up by relevant public health agencies and verified by further confirmatory testing. However, timely outbreak management and re-testing might only be possible when the number of false positive cases is not large. Thus, there is a real risk of wrongful hospital admission or isolation with further unnecessary risk exposure for false-positive individuals or their close contacts. This can be particularly problematic when using throat swabs as the initial diagnostic specimen, given its much lower PPV of 75%. However, the likelihood of false positivity should be much lower for pooled nasal and throat swabs, nasal swabs, and saliva, as indicated by their high and comparable specificity (99%) and PPVs (93–97%).

By contrast, false negativity has more severe implications in the evolving COVID-19 pandemic, as cases not detected by the test would not be isolated and followed up with contact tracing and could seed further community transmission and infection. Although the high sensitivity (97%) of the pooled nasal and throat swab indicated its good detection power, the moderate sensitivities of saliva (85%) and nasal (86%) swabs suggest potential risk missing 14–15% of infected cases.
on average. The much lower and substandard sensitivity of 68% for throat swabs suggests that they could missing almost a third (32%) of infected cases, giving a false negative result. Besides affecting accurate patient diagnosis, inadequate sensitivity to detect SARS-CoV-2 in a positive specimen with low viral load could also hinder the effectiveness of mass testing programmes of high-risk target groups, such as health-care workers, or the entire population.

Although generally regarded as the reference sample for SARS-CoV-2 testing in many countries, nasopharyngeal swabs have numerous limitations that have hindered their efficient and widespread use in ambulatory care settings, including their technical difficulty, procedural discomfort, risk exposure implication, and the resulting expertise and facilities constraints. The comparable diagnostic accuracy of alternative specimen collection methods, as shown in our findings, has practical benefits in clinical practice. Compared with nasopharyngeal swabs, pooled nasal and throat swabs, saliva, and nasal swabs are much less invasive and technically easier to collect. The reduced procedural discomfort might help to prevent the triggering of gag reflexes, coughing, and sneezing and reduce the associated exposure risk for the health-care workers. The reduced requirement for trained health-care workers, high-level personal protective equipment, and negative-pressure facilities for collection of these alternative specimens will allow for their allocation to other competing needs in resource-constrained settings. The relative procedural simplicity could also allow for self-collection by patients or their relatives in different community settings. Similar self-collection approaches have been adopted for the testing of influenza virus infection for diagnostic and surveillance purposes in various settings, with proven validity and acceptability.

In our analysis, the comparable performance profiles of self-collected and health-care worker-collected pooled nasal and throat swabs and nasal swabs, and the generally good performance of self-collected saliva, supported self-collection as a viable option and indicated that it was not associated with any significant impairment of diagnostic accuracy for the diagnosis of SARS-CoV-2 infection. The feasibility, accessibility, and acceptability of the self-collection for testing might help to facilitate the scaling up of SARS-CoV-2 testing in communities, with lower resource requirements and occupational exposure risk for health-care workers.

This review has several limitations. First, substantial heterogeneity was observed in several of the diagnostic performance indicators in studies on saliva and nasal swabs, which varied in terms of the disease prevalence, study location, symptom status of the study sample, and number of candidate genes tested. For example, studies on pooled nose and throat swabs were low in number, and those on nasal swabs collected by health-care workers were underrepresented compared with self-collected nasal swabs, which might have limited our power to assess their diagnostic performance. A stratified comparison of throat swab collection by health-care workers and self-collection was not possible owing to the absence of studies examining its self-collection. Because no study has compared the use of gargle and nasopharyngeal swabs, it was also not possible for us to examine the comparative performance of gargle. Second, publication bias and selective reporting might have resulted in overestimation of some of the performance indicators we examined if studies with null or negative diagnostic performance were less likely to be published. Although only a small number of relevant primary studies are available, our extended search of multiple literature databases and the inclusion of preprints should have helped to minimise the risk of publication bias in our review. Third, geographical coverage was skewed, with most studies of saliva and nasal swabs done in the USA and only a few from in European, Mediterranean, or Asian countries. Fourth, because the heterogeneity remained high in most stratified analyses, factors contributing to the residual heterogeneity might not have been accounted for and affected our observed results. Detailed exploration of the adjusted impact of these factors identified in subgroups analyses by use of a multivariate meta-regression approach was not possible with the small sample size and reduced power due to a small number of available studies. Finally, our study was primarily focused on the diagnosis of patients presenting with symptoms or history of exposure risk in an ambulatory care setting. Although this represented the most common clinical health care seeking scenario, our findings might have reduced generalisability to other settings with different disease prevalence or symptom profiles, such as specialist hospital wards or tertiary referral centres where infection is more likely, mass screening of individuals without symptoms, or testing an entire population with close to zero prevalence. Because our results indicated that the reported sensitivity and PPV were lower in studies done in settings with lower disease prevalence and that including asymptomatic individuals in the sample might contribute to heterogeneity, further prospective study is warranted to examine the effect of alternative sampling approaches on diagnostic performance when used in these settings.

In summary, in this review of all relevant published studies, we synthesised the pooled estimates of the diagnostic performance of different sampling approaches and found that, compared with the gold standard of nasopharyngeal swabs, pooled nasal and throat swabs offered the best diagnostic performance of the alternative sampling approaches for diagnosis of SARS-CoV-2 infection. Self-collection of pooled nasal and throat swabs appeared to be a viable option and did not associate with any significant impairment of diagnostic accuracy. Our results could inform evidence-based clinical practice, including the choice of suitable alternative sampling
approaches for the diagnosis of SARS-CoV-2 infection in the community to enable efficient downstream clinical and public health management, especially in situations where nasopharyngeal swabs are not practically feasible due to reduced manpower and expertise, lack of protective facilities, or overloaded diagnostic testing need. With the added advantages of being less invasive and technically demanding, these alternative sampling approaches would help to boost accessibility and facilitate the efficient scaling up SARS-CoV-2 testing in a community setting. Additionally, our pooled analysis result also provides a framework for the proper interpretation of testing results using different samples.

Contributors
GML and DKMI conceived and designed the study. NNYT and HCS screened literature and extracted data. KYN assisted with data extraction. NNYT and HCS had access to and verified the data. NNYT and DKMI wrote the first draft of the manuscript, and all authors provided critical review and revision of the text and approved the final version. DKMI and had final responsibility for the decision to submit for publication.

Declaration of interests
BJC consults for Roche and Sanofi Pasteur. All other authors declare no competing interests.

Data sharing
The data supporting this meta-analysis are from previously reported studies and datasets, which have been cited. The processed data are available from the corresponding author, upon reasonable request.

Acknowledgments
This project was supported by the Theme-based Research Scheme (T11-712/19-N) of the Research Grants Council of the Hong Kong Special Administrative Region Government. This project was supported by the Theme-based Research Scheme of the Research Grants Council of the Hong Kong Special Administrative Region Government. This work was also supported by the National Natural Science Foundation of China (Nos. 81671657, 82071485, 81822025, and 81471192). This research was supported by the National Key Research and Development Program of China (Nos. 2018YFC2202200, 2018YFC2203500, and 2016YFC1202104), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB32060000), and the National Medical Science and Technology Major Project (2017ZX09301003-002). This work was supported by the Beijing Natural Science Foundation (L212011, L2020011), the National Key Research and Development Program of China (Nos. 2018YFC2202200, 2018YFC2203500, and 2016YFC1202104), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB32060000), and the National Medical Science and Technology Major Project (2017ZX09301003-002). This work was supported by the Beijing Natural Science Foundation (L212011, L2020011).

References
1. WHO. Weekly epidemiological update on COVID-19. March 22, 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-march-2021 (accessed March 23, 2020).
2. Garcia LF. Immune Response, inflammation, and the clinical spectrum of COVID-19. Front Immunol 2020; 11: 1441.
3. Mohammadi A, Esmaeildelsh E, Li Y, Bosch RJ, Li JZ. SARS-CoV-2 detection in different respiratory sites: a systematic review and meta-analysis. EbioMedicine 2020; 59: 102903.
4. Cao W, Li T. COVID-19: towards understanding of pathogenesis. Cell Res 2020; 30: 367-69.
5. WHO. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance, 19 March 2020. Geneva: World Health Organization, 2020.
6. Centers for Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19. July 8, 2020. Centers for Disease Control and Prevention, 2020. https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html (accessed Sept 22 2020).
7. Marty FM, Chen K, Verrill KA. How to obtain a nasopharyngeal swab specimen. N Engl J Med 2020; 382: 276.
8. Karligkiotis A, Arosio A, Castelnuovo P. How to obtain a nasopharyngeal swab specimen. N Engl J Med 2020; 383: e14.
9. Petitt SD, Jerome KR, Rouquie D, et al. ‘All In’: a pragmatic framework for COVID-19 testing and action on a global scale. EMBO Mol Med 2020; 12: e12614.
10. Valentine-Graves M, Hall E, Guest JL, et al. At-home self-collection of saliva, oropharyngeal swabs and dried blood spots for SARS-CoV-2 diagnosis and serology: Post-collection acceptability of specimen collection process and patient confidence in specimens. PLoS One 2020; 15: e0236775.
11. Tajima Y, Suda Y, Yano K. A case report of SARS-CoV-2 confirmed in saliva specimens up to 37 days after onset: Proposal of saliva specimen for COVID-19 diagnosis and virus monitoring. J Infect Chemother 2020; 26: 1086–89.
12. Pinninti S, Trivedi C, Pati SK, et al. Comparing nasopharyngeal and mid-turbinate nasal swab testing for the identification of SARS-CoV-2. Clin Infect Dis 2020; published online June 29. https://doi.org/10.1093/cid/ciaa882.
13. Harrington A, Cox B, Snowden J, et al. Comparison of Abbott ID Now and Abbott m2000 methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from symptomatic patients. J Clin Microbiol 2020; 58: e00798-20.
14. Rhoode DD, Cherian SS, Roman K, Stempak LM, Schmoter CL, Sadri N. Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA emergency use authorization methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs for patients diagnosed with COVID-19. J Clin Microbiol 2020; 58: e00760-20.
15. Nachtigall FX, Pereira A, Trefymchuk OS, Santos LS. Detection of SARS-CoV-2 in nasopharyngeal swabs using MALDI-MS. Nat Biotechnol 2020; 38: 1168–73.
16. Palmas G, Moriondo M, Trapani S, et al. Nasal swab as preferred clinical specimen for COVID-19 testing in children. Pediatr Infect Dis J 2020; 39: e267-70.
17. Basu A, Zinger T, Inglima K, et al. Performance of Abbott ID Now COVID-19 rapid nucleic acid amplification test using nasopharyngeal swabs transported in viral transport media and dry nasal swabs in a New York City academic institution. J Clin Microbiol 2020; 58: e01136-20.
18. Petruzzi G, De Virgilio A, Pichi B, et al. COVID-19: Nasal and oropharyngeal swab. Head Neck 2020; 42: 1103–04.
19. Berenger BM, Fonseca K, Schneider AR, Hu J, Zelaya N. Sensitivity of nasopharyngeal, nasal and throat swabs for the detection of SARS-CoV-2. medRxiv 2020; published online May 8. https://doi.org/10.1001/2020.05.05.20084889 (preprint).
20. Guest JL, Sullivan PS, Valentine-Graves M, et al. Suitability and sufficiency of telehealth clinician-observed, patient-collected samples for SARS-CoV-2 testing: the iCollect cohort pilot study. JMIIR Public Health Surveillance 2020; 6: e19731.
21. McCulloch DJ, Kim AF, Wilcox NC, et al. Comparison of unsupervised home self-collected midnasal swabs with clinician-collected nasopharyngeal swabs for SARS-CoV-2 infection. JAMA Netw Open 2020; 3: e2016382.
22. Xu CIH, Raval M, Schnall JA, Kwong JC, Holmes NE. Duration of respiratory and gastrointestinal viral shedding in children with SARS-CoV-2: a systematic review and synthesis of data. Pediatr Infect Dis J 2020; 39: e249–56.
23. Fakherman O, Dehghannejad M, Khaderni A. Saliva as a diagnostic specimen for detection of SARS-CoV-2 in suspected patients: a scoping review. Infect Dis Poverty 2020; 9: 100.
24. Weiss A, Jellouli M, Sommers MOA. Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: a systematic review and meta-analysis. EbioMedicine 2020; 58: 102916.
25. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, et al. False-negative results of initial RT-PCR assays for COVID-19: a systematic review. medRxiv 2020; published online Aug 13. https://doi.org/10.1016/j.ijid.2020.04.16.20066787 (preprint).
26. Zhu J, Gou J, Xu Y, Chen X. Viral dynamics of SARS-CoV-2 in saliva from infected patients. J Infect 2020; 81: e48–50.
27. Bwire GM, Majigo MY, Njoro BJ, Mawazo A. Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens: a systematic review and meta-analysis. J Med Virol 2021; 93: 719–25.
28. Böger B, Fachi MM, Vilhena RO, Cobere AF, Tonin FS, Pantorolto R. Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19. Am J Infect Control 2021; 49: 21–29.
29. Mawaddah A, Gendeih HS, Lum SG, Marino MB. Upper respiratory tract sampling in COVID-19. Malays J Pathol 2020; 42: 23–35.
30. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. Performance of saliva, oropharyngeal swabs, and nasal swabs for SARS-CoV-2 molecular detection: a systematic review and meta-analysis. medRxiv 2020; published online Nov 13. https://doi.org/10.1016/j.ijid.2020.11.12.20230748 (preprint).
Nasal-swab testing misses patients with low SARS-CoV-2 viral loads. medRxiv 2020; published online Feb 20. https://doi.org/10.1101/medrxiv.24424.

Nasal-swab testing misses patients with low SARS-CoV-2 viral loads. medRxiv 2020; published online Feb 20. https://doi.org/10.1101/medrxiv.24424.

Nasal-swab testing misses patients with low SARS-CoV-2 viral loads. medRxiv 2020; published online Feb 20. https://doi.org/10.1101/medrxiv.24424.

Nasal-swab testing misses patients with low SARS-CoV-2 viral loads. medRxiv 2020; published online Feb 20. https://doi.org/10.1101/medrxiv.24424.
73 Martinez RM. Clinical samples for SARS-CoV-2 detection: review of the early literature. Clin Microbiol News 2020; 42: 121–27.
74 Goyal S, Prasert K, Prapatri P, et al. The acceptability and validity of self-collected nasal swabs for detection of influenza virus infection among older adults in Thailand. Influenza Other Respir Viruses 2017; 11: 412–17.
75 Ip DKM, Schutten M, Fang VJ, et al. Validation of self-swab for virologic confirmation of influenza virus infections in a community setting. J Infect Dis 2012; 205: 631–34.
76 Sueki A, Matsuda K, Yamaguchi A, et al. Evaluation of saliva as diagnostic materials for influenza virus infection by PCR-based assays. Clin Chim Acta 2016; 453: 71–74.
77 To KK, Lu L, Yip CC, et al. Additional molecular testing of saliva specimens improves the detection of respiratory viruses. Emerg Microbes Infect 2017; 6: e49.
78 Song F, Khan KS, Dinnes J, Sutton AJ. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 2002; 31: 88–95.